Patent ID: 6429317
Filing Date: 2002-08-06
Classification: A61P,C07C,C07D,C40B

Abstract:
A compound of the Formula I: R1 is selected from the group consisting of hydrogen, â€”OR4, â€”SR5, C1-C3 alkyl, C2-C3 alkenyl, halo, â€”CN, â€”COR4bâ€², and â€”OC(O)â€”R15; R2 is selected from the group consisting of C1-C10 alkyl; substituted C1-C10 alkyl wherein the alkyl group is substituted with from one to five substituents selected from the group consisting of C2-C6 alkenyl, halo, â€”CF3, â€”OR4a, â€”SR4a, â€”CO2R6a, C3-C8 cycloalkyl, and â€”CN; wherein R4a, R5a, and R6a are independently selected from the group consisting of hydrogen, C1-C3 alkyl, and phenyl; C2-C10 alkenyl; C3-C8 cycloalkyl; aryl selected from the group consisting of phenyl, biphenyl, and naphthyl; substituted aryl wherein the aryl group is selected from the group consisting of phenyl, biphenyl, and naphthyl and is substituted with from one to three substituents selected from the group consisting of halogen(s), â€”CF3, NO2, â€”CN, C1-15-alkyl, C2-5-alkenyl, C2-5-alkynyl, â€”COR6aâ€², â€”SR5aâ€², C3-C8 cycloalkyl, C5-C8 cycloalkenyl, and phenyl, wherein R4aâ€², R5aâ€², and R6aâ€² are each independently selected from hydrogen, â€”CF3, C1-C3 alkyl, phenyl, and â€”C1-C3 alkylphenyl and provided that there is not more than one substituent selected from the group consisting of phenyl, C3-C8 cycloalkyl, and C5-C8 cycloalkenyl; heteroaryl wherein the heteroaryl is optionally fused with a phenyl group and is selected from the group consisting of thiophene, pyrrole, furan, oxazole, pyrazole, imidazole, thiazole, purine, triazoles, thiadiazoles, pyridine, quinoline, isoquinoline, phenanthrine, 5,6-cycloheptenopyridine, pyridazines, cinnolines, phthalazines, pyrazines, pyrimidines, quinazolines; substituted heteroaryl wherein the heteroaryl group is optionally be fused with a phenyl group and is selected from the group consisting of thiophene, pyrrole, furan, oxazole, pyrazole, imidazole, thiazole, purine, triazoles, thiadiazoles, pyridine, quinoline, isoquinoline, phenanthrine, 5,6-cycloheptenopyridine, pyridazines, cinnolines, phthalazines, pyrazines, pyrimidines, quinazolines and is substituted at a carbon atom with a substituent selected from the group consisting of C1-6-alkyl, â€”CF3, phenyl, benzyl, and thienyl; R4 is hydrogen or C1-C3 alkyl; R5 is hydrogen or C1-C3 alkyl; R10 is selected from the group consisting of hydrogen, carbonyl, halo, and C1-C3 alkyl; R11 is selected from the group consisting of hydrogen and C1-C3 alkyl; R12 is independently selected from the group consisting of hydrogen, C1-C10 alkyl, and phenyl; R13 is independently selected from the group consisting of hydrogen, C1-C10 alkyl, and phenyl; or R12 and R13 together with the nitrogen to which they are attached form a group of the formula II: â€ƒor IIâ€² wherein the IIâ€² group is a group of Formula II which is unsaturated; or R11 and R12 together with the nitrogen and carbon to which they are bound can join to form a three to six membered ring; R14 is selected from the group consisting of H, halo, C1-C3 alkyl, and â€”OR16; R15 is C1-C3 alkyl or phenyl; R16 is C1-C3 alkyl; R17 is independently selected from the group consisting of hydrogen, â€”OR4, â€”SR5â€², C1-C3 alkyl, C2-C3 alkenyl, halo, â€”CN, â€”COR4b, and â€”OC(O)â€”R15â€²R4b and R4bâ€² are each independently selected from hydrogen and C1-C3 alkyl; R15â€² is C1-C3 alkyl or phenyl; R4â€² is hydrogen or C1-C3 alkyl; R5â€² is hydrogen or C1-C3 alkyl; X is selected from the group consisting of CH2, O, S, NH, carbonyl, and a bond; nâ€² is 0 to 2; mâ€² is 0 to 2; n is 0 to 3; or a pharmaceutically acceptable salt or solvate thereof.